|Bid||5.06 x 900|
|Ask||12.20 x 3000|
|Day's Range||5.05 - 5.25|
|52 Week Range||4.60 - 5.89|
|Beta (3Y Monthly)||-0.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019 - Nov 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.67|
Began trading under new ticker symbol, XAIR, on the NASDAQ stock exchange on July 15, 2019 Anticipate submitting a PMA for LungFit™* for the treatment of persistent pulmonary.
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate in the BTIG Biotechnology Conference being held at the St. Regis Hotel in New York, NY on August 12, 2019. Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.
GARDEN CITY, N.Y. and REHOVOT, Israel, July 30, 2019 -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing.